56 related articles for article (PubMed ID: 29552167)
1. Nimotuzumab for COVID-19: case series.
Abdo Cuza AA; Ávila JP; Martínez RM; González JJ; Aspuro GP; Gutiérrez Martínez JA; Suzarte MR; Hernández DS; Añé-Kouri AL; Ramos TC
Immunotherapy; 2021 Nov; ():. PubMed ID: 34806405
[TBL] [Abstract][Full Text] [Related]
2. Cucumber-Derived Nanovesicles Containing Cucurbitacin B for Non-Small Cell Lung Cancer Therapy.
Chen T; Ma B; Lu S; Zeng L; Wang H; Shi W; Zhou L; Xia Y; Zhang X; Zhang J; Chen J
Int J Nanomedicine; 2022; 17():3583-3599. PubMed ID: 35974872
[TBL] [Abstract][Full Text] [Related]
3. Novel single-domain antibodies against the EGFR domain III epitope exhibit the anti-tumor effect.
Chen T; Liu X; Hong H; Wei H
J Transl Med; 2020 Oct; 18(1):376. PubMed ID: 33023595
[TBL] [Abstract][Full Text] [Related]
4. Downregulation of microRNA‑21 expression inhibits proliferation, and induces G1 arrest and apoptosis via the PTEN/AKT pathway in SKM‑1 cells.
Li G; Song Y; Li G; Ren J; Xie J; Zhang Y; Gao F; Mu J; Dai J
Mol Med Rep; 2018 Sep; 18(3):2771-2779. PubMed ID: 30015844
[TBL] [Abstract][Full Text] [Related]
5. Nimotuzumab for Patients With Inoperable Cancer of the Head and Neck.
Crombet Ramos T; Mestre Fernández B; Mazorra Herrera Z; Iznaga Escobar NE
Front Oncol; 2020; 10():817. PubMed ID: 32537431
[TBL] [Abstract][Full Text] [Related]
6. Antitumor activity of nimotuzumab in combination with cisplatin in lung cancer cell line A549
Yang Y; Zhou W; Wu J; Yao L; Xue L; Zhang Q; Wang Z; Wang X; Dong S; Zhao J; Yin D
Oncol Lett; 2018 Apr; 15(4):5280-5284. PubMed ID: 29552167
[TBL] [Abstract][Full Text] [Related]
7. Sensitisation of human lung adenocarcinoma A549 cells to radiotherapy by Nimotuzumab is associated with enhanced apoptosis and cell cycle arrest in the G2/M phase.
Lin S; Yan Y; Liu Y; Gao CZ; Shan D; Li Y; Han B
Cell Biol Int; 2015 Feb; 39(2):146-51. PubMed ID: 25044496
[TBL] [Abstract][Full Text] [Related]
8. Induction of different cellular arrest and molecular responses in low EGFR expressing A549 and high EGFR expressing A431 tumor cells treated with various doses of
Suman S; Priya R; Kameswaran M
Int J Radiat Biol; 2020 Sep; 96(9):1144-1156. PubMed ID: 32657634
[TBL] [Abstract][Full Text] [Related]
9. In vitro synergistic antitumor efficacy of sequentially combined chemotherapy/icotinib in non‑small cell lung cancer cell lines.
Wang MC; Liang X; Liu ZY; Cui J; Liu Y; Jing L; Jiang LL; Ma JQ; Han LL; Guo QQ; Yang CC; Wang J; Wu T; Nan KJ; Yao Y
Oncol Rep; 2015 Jan; 33(1):239-49. PubMed ID: 25370413
[TBL] [Abstract][Full Text] [Related]
10. Nimotuzumab enhances radiation sensitivity of NSCLC H292 cells in vitro by blocking epidermal growth factor receptor nuclear translocation and inhibiting radiation-induced DNA damage repair.
Teng K; Zhang Y; Hu X; Ding Y; Gong R; Liu L
Onco Targets Ther; 2015; 8():809-18. PubMed ID: 25926742
[TBL] [Abstract][Full Text] [Related]
11. Study of the antitumor mechanisms of apiole derivatives (AP-02) from Petroselinum crispum through induction of G0/G1 phase cell cycle arrest in human COLO 205 cancer cells.
Wu KH; Lee WJ; Cheng TC; Chang HW; Chen LC; Chen CC; Lien HM; Lin TN; Ho YS
BMC Complement Altern Med; 2019 Jul; 19(1):188. PubMed ID: 31351461
[TBL] [Abstract][Full Text] [Related]
12. Overexpression of wildtype EGFR is tumorigenic and denotes a therapeutic target in non-small cell lung cancer.
Xu N; Fang W; Mu L; Tang Y; Gao L; Ren S; Cao D; Zhou L; Zhang A; Liu D; Zhou C; Wong KK; Yu L; Zhang L; Chen L
Oncotarget; 2016 Jan; 7(4):3884-96. PubMed ID: 26646697
[TBL] [Abstract][Full Text] [Related]
13. S-1 and Cisplatin With or Without Nimotuzumab for Patients With Untreated Unresectable or Metastatic Gastric Cancer: A Randomized, Open-Label Phase 2 Trial.
Du F; Zheng Z; Shi S; Jiang Z; Qu T; Yuan X; Sun Y; Song Y; Yang L; Zhao J; Wang J; Chi Y
Medicine (Baltimore); 2015 Jun; 94(23):e958. PubMed ID: 26061330
[TBL] [Abstract][Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
